Bella Donna Pharma
ActiveThe annual accounts of Bella Donna Pharma for fiscal year 2025 show a net loss of 68% of the equity at the start of that year. The 2025 annual accounts show equity of €17k and a net result of €-36k. Equity is growing by ~3.6% per year across the filed fiscal years. Its solvency ranks better than 14% of 10253 sector peers (fiscal year 2025). The company has been active since 2016 and the Belgian State Gazette contains no insolvency or warning signals. The computed 12-month bankruptcy probability is 0.9% (low).
Checked score
Score 2025
44
/ 100
Weak
The score weighs solvency, liquidity, profitability and financial development. Bankruptcy probability contributes 35%. Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability34▼-32
Solvency28▼-4
Growth32▼-20
Track record100
Bankruptcy probability, 12 months
0.9%
Low
0%0.5%1.5%4%10%≥ 25%
Credit up to €500 at 30 days only on tighter terms
Net loss of at least half of total assets or of the equity at the start of the financial year.
Liquidity short (current ratio 0.87 against 1.0 in 2024; short-term debt: 41.2% and cash: 6.1% of total assets), and 97.5% of the assets are financed with debt.
Credit advice for your own amount and term
Signals
Six signals. The signal on the left, the evidence on the right.
+raises risk○neutral
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 47
Relative position
BE, all sectors
reference
Sector 47
higher
← fewer bankruptcies
more bankruptcies →
raises risk · Annual accounts: weaker financial profile
The latest annual accounts show a weaker profile in solvency, result or liquidity than companies that stay afloat.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
2.5%
Return on assets
-5.5%
Age of the figures
12 mo
raises risk · Weak solvency vs sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 14% of 10253 sector peers (2025).
NBB · sector comparisonPosition among 10253 sector peers
Solvency
better than 14%
← weakest
strongest →
neutral · Latest accounts filed on time
The financial year that closed on 30-09-2025 was due by 30-04-2026 and was filed on 06-03-2026, 55 days ahead of the deadline.
NBB · 9 filingsDeviation from the deadline
2025
55 d early
2024
58 d early
2023
19 d early
2022
30 d early
2021
20 d late
2020
53 d early
2019
56 d early
← before the deadline
after the deadline →
neutral · The next deadline is still running
The next financial year closes on 30-09-2026 and is due by 30-04-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
16-09-2026 today30-09-2026 close30-04-2027 deadline
Financials · fiscal year 2025, abbreviated schema
Equity
€17k▼ 68.3%
2024 · €53k
2018: €23k
2019: €36k
2020: €51k
2021: €59k
2022: €43k
2023: €52k
2024: €53k
2018 → 2025
Total assets
€655k▼ 9.2%
2024 · €722k
2018: €1.04M
2019: €970k
2020: €934k
2021: €891k
2022: €831k
2023: €808k
2024: €722k
2018 → 2025
Net result
€-36k
2024 · €333
2018: €31k
2019: €13k
2020: €16k
2021: €8k
2022: €-16k
2023: €9k
2024: €333
2018 → 2025
Working capital
€-35k
2024 · €200
2018: €-28k
2019: €-18k
2020: €-5k
2021: €-1k
2022: €-19k
2023: €-5k
2024: €200
2018 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20212022202320242025Trend
Equity€59k-€43k▼ 27.0%€52k▲ 21.4%€53k▲ 0.6%€17k▼ 68.3%
Operating result€21k-€-4k€21k€13k▼ 37.7%€-24k
Net result€8k-€-16k€9k€333▼ 96.4%€-36k
Turnover and EBIT margin not published: the abbreviated or micro schema does not require them.
Result per fiscal year
Operating resultNet result
The operating result turns negative in 2025: a loss of €24k after €13k in 2024, the lowest result in the available series.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €655k
Fixed assets
€420k▼ 12.2%
Current assets
€235k▼ 3.2%
Equity and liabilities €655k
Equity
€17k▼ 68.3%
Debt
€639k▼ 4.5%
The debt ratio rises from 92.7% to 97.5%. Equity and debt are lower.
Key figures and ratios
EBITDA
€34k▼
2024 · €73k
Cash flow
€23k▼
2024 · €60k
Solvency
2.5%▼
2024 · 7.3%
Current ratio
0.87▼
2024 · 1.00
Quick ratio
0.41▼
2024 · 0.53
Debt / equity
38.26▲
2024 · 12.71
ROE
-215.4%▼
2024 · 0.6%
ROA
-5.5%▼
2024 · 0.0%
Interest coverage
2.67▼
2024 · 5.65
Debt
€639k▼
2024 · €669k
Debt ≤ 1 year
€270k▲
2024 · €242k
Debt > 1 year
€366k▼
2024 · €424k
Staff costs
€67k▼
2024 · €73k
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2025 against 2024
Balance sheet
Code20242025
Assets
Total assets20/58€722k€655k▼
Fixed assets21/28€479k€420k▼
Intangible fixed assets21€53k€27k▼
Tangible fixed assets22/27€426k€394k▼
Land and buildings22€397k€380k▼
Plant, machinery and equipment23€28k€13k▼
Furniture and vehicles24€690€275▼
Current assets29/58€243k€235k▼
Stocks and contracts in progress3€115k€124k▲
Stocks30/36€115k€124k▲
Amounts receivable within one year40/41€47k€66k▲
Trade receivables40€45k€54k▲
Other amounts receivable41€2k€12k▲
Cash at bank and in hand54/58€72k€40k▼
Deferred charges and accrued income490/1€9k€4k▼
Equity and liabilities
Total equity and liabilities10/49€722k€655k▼
Equity10/15€53k€17k▼
Contributions10/11€20k€20k=
Reserves13€781€781=
Non-distributable reserves130/1€781€781=
Reserves not available under the articles1311€781€781=
Profit (loss) carried forward14€32k€-4k▼
Amounts payable17/49€669k€639k▼
Amounts payable after more than one year17€424k€366k▼
Financial debts170/4€424k€366k▼
Amounts payable within one year42/48€242k€270k▲
Current portion of amounts payable after more than one year42€57k€58k▲
Trade debts44€62k€78k▲
Suppliers440/4€62k€78k▲
Taxes, remuneration and social security45€10k€12k▲
Taxes450/3€2k€2k▼
Remuneration and social security454/9€7k€10k▲
Other amounts payable47/48€113k€122k▲
Accrued charges and deferred income492/3€2k€2k▲
Income statement
Code20242025
Remuneration, social security and pensions62€73k€67k▼
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€60k€59k▼
Other operating charges640/8€6k€3k▼
Gross operating margin9900€153k€103k▼
Operating profit (loss)9901€13k€-24k▼
Financial income75/76B€1k€1k▲
Recurring financial income75€1k€1k▲
Financial charges65/66B€13k€13k▼
Recurring financial charges65€13k€13k▼
Profit (loss) for the period before taxes9903€1k€-36k▼
Income taxes67/77€968-
Profit (loss) for the period9904€333€-36k▼
Profit (loss) for the period to be appropriated9905€333€-36k▼
Appropriation of the result
Profit (loss) to be appropriated9906€32k€-4k▼
Profit (loss) brought forward from the previous period14P€32k€32k▲
Social balance
Average headcount (FTE)90871.01.0=
The notes to these accounts (10 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
06-03
NBB filing
Annual accounts filed
fiscal year 2025 · abbreviated schema
2025
30-09
Financial
Weakest financial yearnet €-36k ▼10908%
Net result drops to €-36k, the lowest in the series.
03-03
NBB filing
Annual accounts filed
fiscal year 2024 · abbreviated schema
2024
11-04
NBB filing
Annual accounts filed
fiscal year 2023 · abbreviated schema
2023
30-09
Financial
Back to profitnet €9k
Net result €9k after one loss-making year.
31-03
NBB filing
Annual accounts filed
fiscal year 2022 · micro schema
2022
20-05
NBB filing
Annual accounts filed
fiscal year 2021 · micro schema · 20 days late
2021
08-03
NBB filing
Annual accounts filed
fiscal year 2020 · abbreviated schema
2020
05-03
NBB filing
Annual accounts filed
fiscal year 2019 · abbreviated schema
2019
05-04
NBB filing
Annual accounts filed
fiscal year 2018 · abbreviated schema
2018
13-03
NBB filing
Annual accounts filed
fiscal year 2017 · abbreviated schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
2 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Scherpenheuvel-Zichem · 1 establishment unit since 2016
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Ter Elzen 213271 Scherpenheuvel-ZichemGround area
1,639 m²
Building footprint
314 m²
Volume, LiDAR
1,955 m³
Parcel 24129E0003/00K003, Flanders · tallest building 9.7 m, ±2 floors. Linked by address, not a title deed.
1 establishment unit
Bella Donna Pharma
since 20162.251.799.966
1 parcel
Flanders
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 24129E0003/00K003 | Flanders | 1,639 m² | 1 · 313 m² | 9.7 m · 2 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Similar companies · same sector, comparable size
PHARMACIE DU PRINCE D'ORANGE
BE 0809.640.192
Ciney · Eq €17k
Pharmacie Flawinne
BE 0428.347.149
Jodoigne · Eq €17k
Liesap
BE 0776.459.858
Wichelen · Eq €17k
APHARGA
BE 0762.565.401
Ferrières · Eq €16k
SoBayFRo
BE 0671.567.820
Tournai · Eq €17k
Of 5,224 companies in sector 47730 we hold annual accounts for 3,864. 1,267 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded02-03-2016
Fiscal year end30-09
Activities, NACEBEL
47730Retail sale of pharmaceutical products
Sources
Crossroads Bank for EnterprisesNational Bank · 9 filingsAddress and cadastre registers
Data from official sources, last processed on 16-09-2026. Scores and ratios are computed by Checked and are not a credit decision.